| scholarly article | Q13442814 |
| review article | Q7318358 |
| P2093 | author name string | Nayoung Kim | |
| Hun Sik Kim | |||
| P2860 | cites work | A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission | Q87355944 |
| LAG-3, a novel lymphocyte activation gene closely related to CD4 | Q24300309 | ||
| The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function | Q24307921 | ||
| Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule | Q24314704 | ||
| Human and mouse killer-cell inhibitory receptors recruit PTP1C and PTP1D protein tyrosine phosphatases | Q24316052 | ||
| Galectin-9 functionally impairs natural killer cells in humans and mice | Q24317152 | ||
| Recruitment of tyrosine phosphatase HCP by the killer cell inhibitor receptor | Q24318464 | ||
| Identification and molecular cloning of tactile. A novel human T cell activation antigen that is a member of the Ig gene superfamily | Q24336153 | ||
| Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade | Q24535835 | ||
| Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma | Q24629841 | ||
| Safety, activity, and immune correlates of anti-PD-1 antibody in cancer | Q24633070 | ||
| The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity | Q24651041 | ||
| Characterization of the lymphocyte activation gene 3-encoded protein. A new ligand for human leukocyte antigen class II antigens | Q24675169 | ||
| CD155/PVR plays a key role in cell motility during tumor cell invasion and migration | Q24805403 | ||
| Targeting NK-cell checkpoints for cancer immunotherapy | Q39150423 | ||
| Checkpoint Inhibition of KIR2D with the Monoclonal Antibody IPH2101 Induces Contraction and Hyporesponsiveness of NK Cells in Patients with Myeloma | Q39679967 | ||
| The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody | Q39705098 | ||
| CIS is a potent checkpoint in NK cell-mediated tumor immunity | Q39744193 | ||
| Tim-3 mediates phagocytosis of apoptotic cells and cross-presentation | Q39882546 | ||
| GSK 3 inhibition drives maturation of NK cells and enhances their antitumor activity | Q40101568 | ||
| Human NK cell education by inhibitory receptors for MHC class I. | Q40244934 | ||
| High NKG2A expression contributes to NK cell exhaustion and predicts a poor prognosis of patients with liver cancer | Q40333142 | ||
| Increased Tim-3 expression in peripheral NK cells predicts a poorer prognosis and Tim-3 blockade improves NK cell-mediated cytotoxicity in human lung adenocarcinoma. | Q40475767 | ||
| Adaptive NK Cells with Low TIGIT Expression Are Inherently Resistant to Myeloid-Derived Suppressor Cells | Q40583098 | ||
| Identification of a subset of human natural killer cells expressing high levels of programmed death 1: A phenotypic and functional characterization | Q40627446 | ||
| Diacylglycerol Kinase ζ Is a Target To Enhance NK Cell Function | Q40637249 | ||
| LAG-3 does not define a specific mode of natural killing in human | Q41027280 | ||
| Absence of B7.1-CD28/CTLA-4-mediated co-stimulation in human NK cells | Q41048463 | ||
| Interleukin-15 stimulates natural killer cell-mediated killing of both human pancreatic cancer and stellate cells | Q41343761 | ||
| Therapeutic CD94/NKG2A blockade improves natural killer cell dysfunction in chronic lymphocytic leukemia | Q41625025 | ||
| Loss of Fas expression and high expression of HLA-E promoting the immune escape of early colorectal cancer cells | Q41887998 | ||
| Mouse TIGIT inhibits NK-cell cytotoxicity upon interaction with PVR. | Q41965537 | ||
| Diacylglycerol kinase zeta regulates microbial recognition and host resistance to Toxoplasma gondii | Q41978103 | ||
| Primitive neuroectodermal tumor in an ovarian cystic teratoma: natural killer and neuroblastoma cell analysis | Q41978255 | ||
| CTLA-4 is expressed by activated mouse NK cells and inhibits NK Cell IFN-γ production in response to mature dendritic cells. | Q42227771 | ||
| A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma | Q42609665 | ||
| Reversal of natural killer cell exhaustion by TIM-3 blockade | Q43180026 | ||
| HLA-E/β2 microglobulin overexpression in colorectal cancer is associated with recruitment of inhibitory immune cells and tumor progression | Q44503506 | ||
| IL-15, TIM-3 and NK cells subsets predict responsiveness to anti-CTLA-4 treatment in melanoma patients | Q45765887 | ||
| Emerging targets in cancer immunotherapy | Q47682070 | ||
| FDA Approval of Nivolumab for the First-Line Treatment of Patients with BRAFV600 Wild-Type Unresectable or Metastatic Melanoma. | Q48712803 | ||
| Natural killer cell immunotherapies against cancer: checkpoint inhibitors and more. | Q49886174 | ||
| Immune evasion via PD-1/PD-L1 on NK-cells and monocyte/macrophages is more prominent in Hodgkin lymphoma than DLBCL. | Q49961097 | ||
| Regulatory T Cells Suppress Natural Killer Cell Immunity in Patients With Human Cervical Carcinoma. | Q50918790 | ||
| SOCS-mediated immunomodulation of natural killer cells. | Q52612283 | ||
| Cancer immunotherapy using checkpoint blockade. | Q52641912 | ||
| NK cell function triggered by multiple activating receptors is negatively regulated by glycogen synthase kinase-3β. | Q53215393 | ||
| Activated human primary NK cells efficiently kill colorectal cancer cells in 3D spheroid cultures irrespectively of the level of PD-L1 expression. | Q53697011 | ||
| Anti-TIM3 antibody promotes T cell IFN-γ-mediated antitumor immunity and suppresses established tumors | Q56898886 | ||
| Profound Coordinated Alterations of Intratumoral NK Cell Phenotype and Function in Lung Carcinoma | Q56965815 | ||
| Negative regulation of T cell homeostasis by lymphocyte activation gene-3 (CD223) | Q81235526 | ||
| Targeting NK Cells for Anticancer Immunotherapy: Clinical and Preclinical Approaches | Q26752518 | ||
| Nivolumab plus ipilimumab in advanced melanoma | Q27852310 | ||
| Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer | Q27860857 | ||
| Improved Survival with Ipilimumab in Patients with Metastatic Melanoma | Q27861062 | ||
| The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation | Q28066941 | ||
| Features of Memory-Like and PD-1(+) Human NK Cell Subsets | Q28073988 | ||
| CEACAM1 regulates TIM-3-mediated tolerance and exhaustion | Q28115443 | ||
| Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1 | Q28116224 | ||
| PD-1 and its ligands in tolerance and immunity | Q28131650 | ||
| Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion | Q28131654 | ||
| The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity | Q28281686 | ||
| The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions | Q28589215 | ||
| Independent modes of natural killing distinguished in mice lacking Lag3 | Q28591539 | ||
| Cutting edge: molecular analysis of the negative regulatory function of lymphocyte activation gene-3 | Q28594769 | ||
| Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma | Q29615443 | ||
| Pembrolizumab versus Ipilimumab in Advanced Melanoma | Q29618134 | ||
| Up on the tightrope: natural killer cell activation and inhibition | Q29619175 | ||
| Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape | Q29620881 | ||
| The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells. | Q33357894 | ||
| Reversal of NK-cell exhaustion in advanced melanoma by Tim-3 blockade | Q33714165 | ||
| Synergistic signals for natural cytotoxicity are required to overcome inhibition by c-Cbl ubiquitin ligase | Q33745662 | ||
| IL-21-mediated reversal of NK cell exhaustion facilitates anti-tumour immunity in MHC class I-deficient tumours | Q33786422 | ||
| T-cell immunoglobulin and ITIM domain (TIGIT) receptor/poliovirus receptor (PVR) ligand engagement suppresses interferon-γ production of natural killer cells via β-arrestin 2-mediated negative signaling | Q33792958 | ||
| The ζ isoform of diacylglycerol kinase plays a predominant role in regulatory T cell development and TCR-mediated ras signaling | Q33894273 | ||
| Tim-3 and its role in regulating anti-tumor immunity | Q33909020 | ||
| Diacylglycerol kinase ζ limits the generation of natural regulatory T cells | Q33920473 | ||
| Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection | Q34093225 | ||
| Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease | Q34112417 | ||
| Biochemical signaling of PD-1 on T cells and its functional implications | Q34116796 | ||
| Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity | Q34161493 | ||
| Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients | Q34161579 | ||
| Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape | Q34241893 | ||
| T Cell Ig- and mucin-domain-containing molecule-3 (TIM-3) and TIM-1 molecules are differentially expressed on human Th1 and Th2 cells and in cerebrospinal fluid-derived mononuclear cells in multiple sclerosis | Q34321960 | ||
| Molecular checkpoints controlling natural killer cell activation and their modulation for cancer immunotherapy | Q37739485 | ||
| Unifying concepts of MHC-dependent natural killer cell education | Q37900760 | ||
| NK cell MHC class I specific receptors (KIR): from biology to clinical intervention | Q37977617 | ||
| A bird's eye view of NK cell receptor interactions with their MHC class I ligands | Q38568874 | ||
| Human leukocyte antigen E contributes to protect tumor cells from lysis by natural killer cells. | Q38585054 | ||
| Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma. | Q38657175 | ||
| Suppression of Metastases Using a New Lymphocyte Checkpoint Target for Cancer Immunotherapy | Q38801519 | ||
| Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation. | Q38837469 | ||
| The Clinical Significance of Abnormal Tim-3 Expression on NK Cells from Patients with Gastric Cancer. | Q38848984 | ||
| Molecular Pathways: Targeting CD96 and TIGIT for Cancer Immunotherapy | Q38952555 | ||
| Expression of immune checkpoint molecules of T cell immunoglobulin and mucin protein 3/galectin-9 for NK cell suppression in human gastrointestinal stromal tumors | Q38977915 | ||
| LSECtin expressed on melanoma cells promotes tumor progression by inhibiting antitumor T-cell responses | Q39000978 | ||
| The negative regulatory function of the lymphocyte-activation gene-3 co-receptor (CD223) on human T cells | Q34417483 | ||
| Balancing natural killer cell activation through paired receptors | Q34465877 | ||
| Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. | Q34891171 | ||
| HLA-E expression by gynecological cancers restrains tumor-infiltrating CD8⁺ T lymphocytes. | Q35081677 | ||
| Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo | Q35235365 | ||
| TIM-3/Gal-9 interaction induces IFNγ-dependent IDO1 expression in acute myeloid leukemia blast cells | Q35505155 | ||
| Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients | Q35616397 | ||
| Vav1 dephosphorylation by the tyrosine phosphatase SHP-1 as a mechanism for inhibition of cellular cytotoxicity | Q35661770 | ||
| CTLA-4⁺ Regulatory T Cells Increased in Cetuximab-Treated Head and Neck Cancer Patients Suppress NK Cell Cytotoxicity and Correlate with Poor Prognosis | Q35674757 | ||
| PAG-associated FynT regulates calcium signaling and promotes anergy in T lymphocytes | Q35676176 | ||
| Tim-3 is an inducible human natural killer cell receptor that enhances interferon gamma production in response to galectin-9 | Q35876978 | ||
| Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity | Q35909663 | ||
| The adaptor protein Crk controls activation and inhibition of natural killer cells | Q35971591 | ||
| A Phase I Trial of the Anti-KIR Antibody IPH2101 and Lenalidomide in Patients with Relapsed/Refractory Multiple Myeloma. | Q36070261 | ||
| Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25. | Q36293343 | ||
| Bat3 promotes T cell responses and autoimmunity by repressing Tim-3–mediated cell death and exhaustion. | Q36377233 | ||
| A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma | Q36425427 | ||
| Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells | Q36539682 | ||
| Lung tumor microenvironment induces specific gene expression signature in intratumoral NK cells | Q36584068 | ||
| Recruitment of Grb2 and SHIP1 by the ITT-like motif of TIGIT suppresses granule polarization and cytotoxicity of NK cells | Q36603122 | ||
| Repression of GSK3 restores NK cell cytotoxicity in AML patients | Q36768725 | ||
| T cell regulation of natural killer cells | Q36907905 | ||
| Stepwise phosphorylation of p65 promotes NF-κB activation and NK cell responses during target cell recognition | Q36973848 | ||
| Negative signaling by inhibitory receptors: the NK cell paradigm | Q36983705 | ||
| Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family | Q36998864 | ||
| Accelerated tumor growth in mice deficient in DNAM-1 receptor | Q37019655 | ||
| Effects of anti-NKG2A antibody administration on leukemia and normal hematopoietic cells | Q37216218 | ||
| Negative regulation of lymphocyte development and function by the Cbl family of proteins | Q37256994 | ||
| CD28/B7-mediated co-stimulation is critical for early control of murine cytomegalovirus infection | Q37341040 | ||
| Lytic granule polarization, rather than degranulation, is the preferred target of inhibitory receptors in NK cells | Q37346605 | ||
| Controlling natural killer cell responses: integration of signals for activation and inhibition | Q37404156 | ||
| Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies | Q37535232 | ||
| PD-1 mediates functional exhaustion of activated NK cells in patients with Kaposi sarcoma | Q37687323 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | globulins | Q321710 |
| membrane protein | Q423042 | ||
| cell | Q7868 | ||
| immunotherapy | Q1427096 | ||
| blood proteins | Q425056 | ||
| neoplasm | Q1216998 | ||
| hemic and immune systems | Q70202933 | ||
| P304 | page(s) | 2041 | |
| P577 | publication date | 2018-01-01 | |
| 2018-09-10 | |||
| P1433 | published in | Frontiers in Immunology | Q27723748 |
| P1476 | title | Targeting Checkpoint Receptors and Molecules for Therapeutic Modulation of Natural Killer Cells | |
| P478 | volume | 9 |
| Q91387555 | Adding to the checkpoint blockade armamentarium |
| Q60951075 | Blockade of LAG-3 Immune Checkpoint Combined With Therapeutic Vaccination Restore the Function of Tissue-Resident Anti-viral CD8 T Cells and Protect Against Recurrent Ocular Herpes Simplex Infection and Disease |
| Q92883499 | Blockade of PD-1 and LAG-3 Immune Checkpoints Combined with Vaccination Restores the Function of Antiviral Tissue-Resident CD8+ TRM Cells and Reduces Ocular Herpes Simplex Infection and Disease in HLA Transgenic Rabbits |
| Q64987872 | Cancer Immunotherapy Based on Natural Killer Cells: Current Progress and New Opportunities. |
| Q64107453 | Cytotoxicity of Human Hepatic Intrasinusoidal CD56 Natural Killer Cells against Hepatocellular Carcinoma Cells |
| Q92315395 | DNAM-1 Activating Receptor and Its Ligands: How Do Viruses Affect the NK Cell-Mediated Immune Surveillance during the Various Phases of Infection? |
| Q92991305 | DNAM-1 and the TIGIT/PVRIG/TACTILE Axis: Novel Immune Checkpoints for Natural Killer Cell-Based Cancer Immunotherapy |
| Q92095447 | Dissecting the biology of allogeneic HSCT to enhance the GvT effect whilst minimizing GvHD |
| Q89797908 | Ectopic expression of LAG-3 in non-small-cell lung cancer cells and its clinical significance |
| Q91691392 | Human NK cells: surface receptors, inhibitory checkpoints, and translational applications |
| Q101120982 | Immune checkpoint molecules in natural killer cells as potential targets for cancer immunotherapy |
| Q94528590 | In Situ Immune Profiling of Heart Transplant Biopsies Improves Diagnostic Accuracy and Rejection Risk Stratification |
| Q89621123 | Influence of the Tumor Microenvironment on NK Cell Function in Solid Tumors |
| Q92504014 | Mannan-Binding Lectin Regulates Inflammatory Cytokine Production, Proliferation, and Cytotoxicity of Human Peripheral Natural Killer Cells |
| Q93360204 | Neuroendocrine control of natural killer cell function through the checkpoint molecule PD-1 |
| Q91687990 | Progressive Impairment of NK Cell Cytotoxic Degranulation Is Associated With TGF-β1 Deregulation and Disease Progression in Pancreatic Cancer |
| Q90693846 | Targeted Therapies: Friends or Foes for Patient's NK Cell-Mediated Tumor Immune-Surveillance? |
| Q97883506 | Targeting NK Cell Checkpoint Receptors or Molecules for Cancer Immunotherapy |
| Q90093145 | Targeting Natural Killer Cells for Tumor Immunotherapy |
| Q90662000 | The IL-12- and IL-23-Dependent NK Cell Response Is Essential for Protective Immunity against Secondary Toxoplasma gondii Infection |
| Q89534525 | The IUPHAR Guide to Immunopharmacology: connecting immunology and pharmacology |
| Q90176787 | Unleashing Natural Killer Cells in the Tumor Microenvironment-The Next Generation of Immunotherapy? |
Search more.